Of 415 screened patients , 331 were eligible and were randomly assigned to the four treatment groups : evolocumab 140 mg every 2 weeks ( n = 111 ) , evolocumab 420 mg monthly ( n = 110 ) , placebo every 2 weeks ( n = 55 ) , or placebo monthly ( n = 55 ) .